| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5124 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5435 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5854 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5926 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.5997 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6235 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6305 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6396 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6404 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6517 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6815 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.6948 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7070 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7089 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7144 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7173 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7191 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7308 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7320 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7328 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7342 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7604 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7827 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7908 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7942 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.7994 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8005 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8022 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8034 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8058 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8074 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8094 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8173 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8270 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8401 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8424 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8467 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8592 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8745 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8786 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8827 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8881 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8906 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.8929 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9010 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9031 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9034 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9052 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9069 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9069 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9102 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9116 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9123 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9124 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9124 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9140 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9245 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9297 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9311 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9348 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9388 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9422 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9446 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9458 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9502 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9503 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9522 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9609 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9628 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9681 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9732 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9815 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9826 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9837 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 0.9932 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0000 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0000 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0015 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0027 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0130 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0303 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0328 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0334 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0377 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0449 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0458 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0656 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0695 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0755 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0924 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.0958 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1014 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1040 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1045 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1056 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1057 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1143 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1172 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1207 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1226 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1231 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1256 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1286 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1336 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1411 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1435 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1675 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1725 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1795 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1846 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1896 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1911 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.1978 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2024 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2039 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2044 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2058 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2059 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2118 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2152 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2183 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2227 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2231 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2459 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2524 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2564 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2591 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2796 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2865 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.2922 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3032 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3078 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3128 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3289 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3297 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3346 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3640 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3886 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3887 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3919 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.3955 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4039 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4076 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4226 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4487 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4548 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4664 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.4968 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.5396 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.6539 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.6836 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylleucine | 1.7568 | scaled units | Placebo | BASELINE |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|